Welcome to our dedicated page for VERTEX PHARMACEUTICALS / MA SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VERTEX PHARMACEUTICALS / MA's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VERTEX PHARMACEUTICALS / MA's regulatory disclosures and financial reporting.
Vertex Pharmaceuticals executive Carmen Bozic reported an open-market sale of company stock. On March 13, 2026, Dr. Bozic sold 2,329 shares of Vertex common stock at a price of $481.79 per share, as part of routine portfolio activity.
After this transaction, Dr. Bozic directly held 35,405 shares of Vertex common stock, indicating she retains a substantial ownership stake. The sale was carried out under a pre-established Rule 10b5-1 trading plan, meaning it was scheduled in advance under company-approved guidelines rather than timed opportunistically.
Vertex Pharmaceuticals executive Duncan McKechnie sold 2,633 shares of common stock in an open-market transaction. The sale occurred on March 11, 2026, at an average price of $498.42 per share. After the sale, he directly held 12,489 Vertex shares.
The transaction was made under a company-approved Rule 10b5-1 trading plan that Mr. McKechnie entered into on November 25, 2025, indicating the sale was pre-scheduled rather than opportunistic.
Carmen R. Bozic submitted a Form 144 notice to sell Common Stock. The filing lists Fidelity Brokerage Services LLC as the broker and references restricted stock vesting dated 02/26/2025. The form shows a sale recorded on 02/27/2026 and is dated 03/13/2026.
Issuer reported proposed sales of Common Stock via Form 144 by Duncan J. McKechnie. The filing lists two proposed dispositions: $2,394,365.00 for 4,910 shares on 02/25/2026 and $1,158,306.10 for 2,437 shares on 03/04/2026.
The filing also records restricted stock vesting events dated 02/10/2026 and 02/17/2026, including a vesting of 612 compensation shares on 02/17/2026. The entries identify Fidelity Brokerage Services LLC and NASDAQ as custodial/market references.
Vertex Pharmaceuticals executive reports planned share sale
Vertex Pharmaceuticals EVP and Chief Commercial Officer Duncan McKechnie sold 2,437 shares of common stock in an open-market transaction at $475.30 per share. After this sale, he directly holds 15,122 shares. The trade was made under a company-approved Rule 10b5-1 trading plan entered into on 11/25/2025.
Vertex Pharmaceuticals executive Joy Liu sold shares under a pre‑planned program. On March 2, 2026, she completed an open-market sale of 892 shares of Vertex common stock at $495.96 per share. After this transaction, she directly held 22,811 Vertex shares. The sale was made under a company-approved Rule 10b5‑1 trading plan entered into on November 25, 2025.
Issuer reports proposed insider sale and recent transactions. The filing shows 2,437 restricted common shares that vested on 02/13/2026 as compensation. It also discloses a reported sale of 4,910 common shares on 02/25/2026 by Duncan J. McKechnie for $2,394,365.00.
The notice was submitted under Form 144 and lists Fidelity Brokerage Services LLC as the broker. Timing and aggregated proceeds for any proposed disposition are limited to the amounts shown in the filing.
Vertex Pharmaceuticals executive Joy Liu has filed an initial ownership report outlining her equity holdings in the company. As EVP and Chief Legal Officer, she reports direct ownership of 23,703 shares of common stock.
She also reports two grants of stock options (rights to buy shares) covering 7,044 and 5,363 shares, with a footnote indicating that at least one of these option awards is fully vested. The filing does not reflect new purchases or sales but establishes her baseline ownership position.
Vertex Pharmaceuticals CEO & President Reshma Kewalramani reported open-market sales of 40,000 shares of Vertex common stock on February 27, 2026 under a pre-arranged Rule 10b5-1 trading plan entered into on November 17, 2025. The shares were sold at prices ranging from $479.75 to $496.95, and she held 98,278 shares directly after the final transaction.
Vertex Pharmaceuticals EVP and CMO Carmen Bozic sold common stock in a planned transaction. On February 27, 2026, she completed an open-market sale of 2,329 shares of Vertex common stock at an average price of $480.31 per share. After the sale, she directly owned 37,734 shares. The trade was made under a pre-established Rule 10b5-1 trading plan entered on November 20, 2025.